As seen in the chart below, it appears that renewable oil producer Solazyme (SZYM) has begun to stand apart from its supposed industry peer group over the last few months. Although often lumped together with struggling advanced biofuel and biochemical producers such as Amyris (AMRS), Gevo (GEVO), and KiOR (KIOR), Solazyme has begun to distinguish itself as investors begin to comprehend the vast distinctions between these companies. Apart from its superior balance sheet, operational traction, and magnetic appeal to landing industry-leading partners, Solazyme's comparative advantage is beginning to be understood in the company's biotechnology toolkit.
SZYM data by YCharts
Over the past decade, Solazyme has refined its technology to...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|